- Home
- RARE vs EXTR Comparison
RARE vs EXTR Comparison
Compare RARE & EXTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | EXTR |
|---|---|---|
| Founded | 2010 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2013 | 1999 |
Fundamental Metrics
Financial Performance| Metric | RARE | EXTR |
|---|---|---|
| Price | $21.26 | $13.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 5 |
| Target Price | ★ $66.32 | $21.20 |
| AVG Volume (30 Days) | ★ 2.0M | 1.6M |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.31 | ★ 90.91 |
| EPS | N/A | ★ 0.10 |
| Revenue | $673,000,000.00 | ★ $1,140,067,000.00 |
| Revenue This Year | $13.40 | $13.15 |
| Revenue Next Year | $42.83 | $7.52 |
| P/E Ratio | ★ N/A | $144.70 |
| Revenue Growth | ★ 20.13 | 2.05 |
| 52 Week Low | $18.41 | $10.11 |
| 52 Week High | $40.54 | $22.89 |
Technical Indicators
Market Signals| Indicator | RARE | EXTR |
|---|---|---|
| Relative Strength Index (RSI) | 37.40 | 39.74 |
| Support Level | $19.61 | $13.72 |
| Resistance Level | $25.46 | $18.53 |
| Average True Range (ATR) | 0.98 | 0.50 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 39.06 | 40.16 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About EXTR Extreme Networks Inc.
Extreme Networks Inc provides AI-powered cloud networking, focused on delivering simple and secure solutions that help businesses address challenges and enable connections among devices, applications, and users. The group designs, develops, and manufactures wired, wireless, and software-defined wide area network (SD-WAN) infrastructure equipment. It has one reportable segment, the development, marketing, and sale of network infrastructure equipment and related software. The Company operates in three geographical areas: Americas, EMEA, and APAC.